Valvular heart disease secondary prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m (Bot: Removing from Primary care) |
||
Line 27: | Line 27: | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
{{WH}} | |||
{{WS}} | |||
[[Category:Needs content]] | [[Category:Needs content]] | ||
[[Category:Cardiology]] | [[Category:Cardiology]] | ||
[[Category:Valvular heart disease]] | [[Category:Valvular heart disease]] | ||
Latest revision as of 00:38, 30 July 2020
Valvular heart disease Microchapters |
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
Overview
2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary[1]
Recommendations for The Heart Valve Team and Heart Valve Centers of Excellence
Class I |
"1. Patients with severe valvular heart disease should be evaluated by a multidisciplinary heart valve team when intervention is considered. (Level of Evidence: C)" |
Class IIa |
"1. Consultation with or referral to a heart valve center of excellence is reasonable when discussing treatment options for:
|
References
- ↑ Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA; et al. (2014). "2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines". Circulation. doi:10.1161/CIR.0000000000000029. PMID 24589852.